Literature DB >> 16731115

Distribution and likelihood of lymph node metastasis based on the lobar location of nonsmall-cell lung cancer.

Robert J Cerfolio1, Ayesha S Bryant.   

Abstract

BACKGROUND: Despite the use of integrated positron emission tomography and computed tomography scans in patients with nonsmall-cell lung cancer, N2 disease is often missed. Knowledge of the N2 station most likely to be malignant based on the lobar location of the primary may help guide biopsies.
METHODS: A retrospective review of an electronic prospective database of patients with nonsmall-cell lung cancer who underwent positron emission tomography and computed tomography clinical staging and had nodal biopsy or resection with complete lymphadenectomy, or both.
RESULTS: The incidence and location of N2 disease of the 954 patients based on the location of the primary tumor was as follows: for right upper lobe cancers, 27% had N2 disease, most commonly in the 4R (23%); right middle lobe, 15%, most commonly in the 4R (8%) and the 7th station (6%); right lower lobe, 30%, most commonly in the 4R (15%) and the 7th station (14%); left upper lobe, 20%, most commonly in the 6 (16%); and left lower lobe, 22%, most commonly in the 7 (8%). Patients with right middle lobe cancer were more likely to have N1 disease (p = 0.014). Skip metastases (no N1, but N2 disease) was most common with left upper lobe lesions. Patients with right-sided cancers were more likely to have N2 disease compared with patients who had left-sided lesions (27% versus 21%, p = 0.02).
CONCLUSIONS: There is a distinct predilection for the location of N2 disease based on the lobar location of primary nonsmall-cell lung cancer. We recommend the consideration of video-assisted thoracoscopy for biopsy of the 5 and 6 stations for patients with left upper lobe lesions, mediastinoscopy for right upper lobe lesions, and esophageal ultrasound with fine-needle aspiration for right lower lobe, left lower lobe, and right middle lobe lesions. Right-sided lesions are more likely to have N2 disease.

Entities:  

Mesh:

Year:  2006        PMID: 16731115     DOI: 10.1016/j.athoracsur.2005.12.067

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  24 in total

1.  Therapeutic value of lymph node dissection for right middle lobe non-small-cell lung cancer.

Authors:  Hiroaki Kuroda; Yukinori Sakao; Mingyon Mun; Noriko Motoi; Yuichi Ishikawa; Ken Nakagawa; Yasushi Yatabe; Sakae Okumura
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

2.  The fundamental problem of confounding by medical operability in retrospective comparisons of surgery versus stereotactic body radiation therapy for early-stage lung cancer.

Authors:  Vivek Verma; Chad G Rusthoven
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

Review 3.  The use and misuse of positron emission tomography in lung cancer evaluation.

Authors:  Ching-Fei Chang; Afshin Rashtian; Michael K Gould
Journal:  Clin Chest Med       Date:  2011-12       Impact factor: 2.878

Review 4.  Selective lymph node dissection in early-stage non-small cell lung cancer.

Authors:  Han Han; Haiquan Chen
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

Review 5.  [The technique of thoracic lymph node dissection].

Authors:  S Oguzhan; M Mese; M Schirren; M Baladov; J Schirren
Journal:  Chirurg       Date:  2019-12       Impact factor: 0.955

6.  Stereotactic body radiation therapy (SBRT) for early stage lung cancer delivers clinically significant radiation to the draining lymph nodes.

Authors:  Bhupesh Parashar; Prabhsimranjot Singh; Paul Christos; Shruthi Arora; Prashant Desai; A Gabriella Wernicke; Marylynn Delamerced; Dustin Boothe; Dattatreyudu Nori; Ksc Chao
Journal:  J Radiosurg SBRT       Date:  2013

Review 7.  Controversies regarding T status and N status for non-small cell lung cancer.

Authors:  Yanli Mo; Jiayin Peng; Wenmei Su; Xinggui Chen; Aibing Wu; Jinmei Li; Zhixiong Yang
Journal:  Int J Clin Exp Med       Date:  2015-07-15

8.  N2 disease in T1 non-small cell lung cancer.

Authors:  Sebastian A Defranchi; Stephen D Cassivi; Francis C Nichols; Mark S Allen; K Robert Shen; Claude Deschamps; Dennis A Wigle
Journal:  Ann Thorac Surg       Date:  2009-09       Impact factor: 4.330

Review 9.  Post-operative radiation therapy (PORT) in completely resected non-small-cell lung cancer.

Authors:  Yelena Krupitskaya; Billy W Loo
Journal:  Curr Treat Options Oncol       Date:  2009-04-22

Review 10.  Mediastinal staging of NSCLC with endoscopic and endobronchial ultrasound.

Authors:  Neal Navani; Stephen G Spiro; Sam M Janes
Journal:  Nat Rev Clin Oncol       Date:  2009-05       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.